| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ji-Hao Shi, Liang Luo, Xiao-Li Chen, Yi-Peng Pan, Zhou Zhang, Hao Fang, Ying Chen, Wen-Dong Chen and Qian Cao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Zhejiang Medical and Health Science and Technology project |
2020KY608 |
| Natural Science Foundation of Zhejiang Province |
LQ19H030013 |
|
| Corresponding Author |
Qian Cao, MD, PhD, Professor, Department of Gastroenterology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, No. 3 Qingchun E Road, Xin Cheng Shang Quan, Jianggan District, Hangzhou 310016, Zhejiang Province, China. caoq@zju.edu.cn |
| Key Words |
Infliximab; Crohn’s disease; Maintenance therapy; Cost-effectiveness; Outcomes; Direct medical costs |
| Core Tip |
Infliximab maintenance therapy significantly reduced disease severity, improved quality of life, and reduced outpatient clinic visits and hospitalization related to active disease in Chinese patients with moderate to severe Crohn’s disease. Even though the drug acquisition costs of infliximab couldn't be fully offset by the saved medical costs, the cost-effectiveness of infliximab maintenance therapy was highly attractive from the perspective of Chinese health care payers. |
| Publish Date |
2020-11-06 07:36 |
| Citation |
Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i41/6455.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i41.6455 |
